Agilent at AACR 2025: Showcasing next-gen solutions for cancer research and therapeutics

Agilent Technologies (NYSE: A) will participate in the AACR Annual Meeting 2025, taking place April 25–30 in Chicago. The company will highlight new products and partnerships aimed at advancing cancer research, diagnostics, and treatment.

Key solutions and collaborations include:

- Agilent Avida DNA Cancer Panels: Three new panels optimized for liquid biopsy applications, enabling DNA and methylation profiling from a single sample. Designed in alignment with the European OncNGS Consortium’s needs, these panels deliver same-day sequencing-ready libraries.
- SureSelect Cancer CGP Assay and Tagomics Interlace Multiomics Assay: A new combined workflow provides genome-wide epigenetic insights and targeted DNA variant detection, supporting comprehensive cancer profiling.
- SureSelect Cancer Pan Heme Assay: Developed with Roswell Park Comprehensive Cancer Center, this assay covers DNA and RNA mutations in hematologic cancers and includes automation via the Magnis NGS Prep System and QIAGEN Clinical Insight software.
- Agilent and Abcam IHC CDx collaboration: Agilent will develop companion diagnostics using Abcam’s recombinant antibody portfolio, enabling faster assay development for clinical trials.

Agilent will also host an educational session at the AACR Exhibitor Spotlight Theater on April 27. Presenters include Dr. Robert Neely of Tagomics and Dr. Sean Glenn of Roswell Park, who will discuss multiomic profiling and the Pan Heme assay.

Agilent will showcase additional research posters and presentations from customers utilizing Agilent’s technologies.